Skip to content
Screener

Bio-Techne TECH Common Stock

Common Stock at other companies

Danaher logo
DanaherDHR
2B+22,122%
Bruker logo
BrukerBRKR
260M0.0%
10x Genomics, Inc. logo
10x Genomics, Inc.TXG
$2K0.0%
Revvity logo
RevvityRVTY
300M0.0%
Agilent Technologies logo
Agilent TechnologiesA
2B0.0%
Ginkgo Bioworks logo
Ginkgo BioworksDNA
15.8B0.0%

Other financials

Income statement

See full
Revenue$311.4M-1.5%
Gross profit$208.3M-2.9%
Operating income$75.5M+95.0%
Net income$51.0M+126%
EPS (diluted)$0.32+129%

Balance sheet

See full
Cash & equivalents$209.8M+49.2%
Total debt$290.3M-31.4%
Total equity$2.1B+3.3%
Total assets$2.6B-3.5%

Cash flow

See full
Operating cash flow$86.7M+111%
CapEx$9.1M-10.2%
Free cash flow$77.6M+150%

Valuation

See full
Market cap$11.22B+43.5%
Enterprise value$11.3B+39.5%
P/E74.9×+16.9×
P/S9.3×+2.9×

Profitability

See full
Gross margin65%-0.8pp
Operating margin14.2%-7.9pp
Net margin10.9%-6.7pp
FCF margin22.3%+4.0pp

Returns & leverage

See full
Return on equity6.5%-3.9pp
Debt / equity0.1×-0.1×
Current ratio4.5×+0.8×

Where this comes from

Reported directly by Bio-Techne in its filing.

Tagged under the XBRL concept us-gaap:CommonStockValue.

The source filing: Bio-Techne’s 10-Q, filed May 6, 2026.

Filed
May 6, 2026, 4:31 PM EDT
Fiscal quarter
Q3 FY2026
Calendar quarter
Q1 2026
Accession
0001104659-26-056302
Line itemMarch 31, 2026 / (unaudited)June 30, 2025
Other long-term liabilities21,66827,082
Shareholders’ equity:
Undesignated capital stock, no par; authorized 5,000,000 shares; none issued or outstanding
Common stock, par value $.01 per share; authorized 400,000,000; issued and outstanding 156,516,091 and 154,972,196 respectively1,5651,550
Additional paid-in capital1,005,403911,089
Retained earnings1,145,1921,066,049
Accumulated other comprehensive loss(66,856)(59,880)
Total shareholders’ equity2,085,3041,918,808

Item 1. Condensed Consolidated Financial Statements (Unaudited)

FAQ

What is Bio-Techne's common stock?
Bio-Techne (TECH) reported common stock of $1.57M in Q1 2026.
How has Bio-Techne's common stock changed year-over-year?
Bio-Techne's common stock decreased by 0.2% year-over-year, from $1.57M to $1.57M.
What is the long-term trend for Bio-Techne's common stock?
Over 4 years (2021 to 2025), Bio-Techne's common stock has grown at a 41.2% compound annual growth rate (CAGR), from $390K to $1.55M.
What does common stock mean?
The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).

Ask your AI about Bio-Techne's common stock.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude